GSP Crop Science manufactures and sells agricultural chemicals, including insecticides, herbicides, and fungicides, to both industrial partners and retail farmers in India and international markets.
The company possesses a narrow moat based on its portfolio of over 100 patents and first-mover status in off-patent molecules, though the 5% net margin suggests these advantages are partially offset by the commodity nature of the broader agrochemical market.
Management has prioritized backward integration to reduce import dependency and used IPO proceeds to deleverage, though the high EPS decline suggests recent reinvestments have yet to translate into bottom-line growth.
The investment collapsed as the massive divergence between revenue growth and earnings finally resolved in a permanent margin squeeze. Despite holding patents, the company remained a price-taker in a commoditized agrochemical market, unable to pass on rising fuel and labor costs. The reliance on Chinese intermediates became a fatal flaw when supply chains tightened, while the capital previously tied up in backward integration failed to yield the promised returns. Ultimately, the business proved to be a treadmill where increasing sales only served to fund rising operational complexity without ever reaching the bottom line, leading to a massive de-rating by the market.
RichFakir rates GSP Crop Science Ltd's business quality as mediocre — 50/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, GSP Crop Science Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on GSP Crop Science Ltd is: Not rated. A mediocre business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of GSP Crop Science Ltd's fair value is about ₹173 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →